ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
10.90
-0.03 (-0.27%)
At close: Apr 28, 2026, 4:00 PM EDT
10.88
-0.02 (-0.18%)
After-hours: Apr 28, 2026, 7:32 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 25.67, with a low estimate of 21 and a high estimate of 32. The average target predicts an increase of 135.50% from the current stock price of 10.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 2 |
| Buy | 1 | 1 | 1 | 1 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 2 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +92.66% | Apr 21, 2026 |
| Mizuho | Mizuho | Buy Maintains $30 → $24 | Buy | Maintains | $30 → $24 | +120.18% | Apr 13, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2026 |
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +193.58% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +129.36% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
650.25M
from 510.17M
Increased by 27.46%
Revenue Next Year
794.02M
from 650.25M
Increased by 22.11%
EPS This Year
0.97
from 0.60
Increased by 62.35%
EPS Next Year
1.24
from 0.97
Increased by 27.40%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 672.0M | 820.5M | ||||||
| Avg | 650.3M | 794.0M | ||||||
| Low | 622.3M | 760.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.7% | 26.2% | ||||||
| Avg | 27.5% | 22.1% | ||||||
| Low | 22.0% | 16.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.09 | 1.45 | |||
| Avg | 0.97 | 1.24 | |||
| Low | 0.85 | 1.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 82.0% | 48.8% | |||
| Avg | 62.4% | 27.4% | |||
| Low | 42.1% | 10.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.